We believe in equal access to healthcare diagnostics for everyone, everywhere!
We are passionate about enabling more convenient solutions for patient centric sampling, ensuring more reliable test results for healthcare and other providers of tests based on blood or plasma. We believe in equal access to healthcare diagnostics for everyone, everywhere!
Want to learn more?
Projects & Collaborations
Since 2002, Attana research services and systems have improved their customers’ clinical trial success rates by 4x compared to the industry average. In 2021, they launched their first CE IVD-marked device for novel insights into antibody diagnostics. From a drop of blood (10µl), the AVATM laboratory system can both quantify the number of antibodies in a sample as well as determine their neutralizing capacity, in a matter of minutes. On 19th of May 2022, Attana announced an updated CE IVD marking for its AVATM SARS-CoV-2 IgG Immunoassay kit. This now includes capillary blood samples using Capitainer®qDBS which enables the technology to be used with self-sampling.
In combination with Capitainer® qDBS, Attana today offers high quality diagnostic analyses in a wider scope of studies than previously possible.
For more information visit www.attana.com
Altasciences is a forward-thinking, mid-size contract research organization strategically located across North-America, offering biopharmaceutical companies of all sizes a proven, flexible approach to preclinical and clinical studies, from lead candidate selection to proof of concept, and beyond. In addition to supporting clinical sites and preclinical testing facilities, their state-of-the-art bioanalytical laboratories provide stand-alone services for both small and large molecules.
With over 25 years of experience, Altasciences has a proven track record for delivering the accurate and precise drug concentrations that sponsors depend upon for successful regulatory submission. Keeping current in the evolving landscape of microsampling solutions for patient-centric healthcare and remote sampling, Altasciences’ evaluation of the Capitainer qDBS found the device straightforward to implement whilst being extremely capable of delivering accurate and precise blood volumes independent of hematocrit level. This allowed all precision and accuracy data for the quantitation of an anti-epileptic drug panel from dried blood spot to readily meet acceptance criteria as recently described at the AAPS (provide link here, which Capitainer should already have).
For more information visit www.altasciences.com
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No H2020-SEMINST-868807.